Schrödinger FY 2024 Software Revenue Growth 6%-13%, Drug Discovery Revenue $30M-$35M, Software Gross Margin Slightly Lower Than 2023, Operating Expense Growth 8%-10%, Cash Used for Operating Activities Above 2023 Levels, Q3 Software Revenue $32M-$34M
Portfolio Pulse from Benzinga Newsdesk
Schrödinger (SDGR) projects FY 2024 software revenue growth of 6%-13% and drug discovery revenue between $30M-$35M. The company expects a slight decrease in software gross margin compared to 2023, with operating expenses growing by 8%-10%. Cash used for operating activities is anticipated to be higher than in 2023. For Q3, software revenue is estimated to be $32M-$34M.
July 31, 2024 | 8:14 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Schrödinger (SDGR) projects FY 2024 software revenue growth of 6%-13% and drug discovery revenue between $30M-$35M. The company expects a slight decrease in software gross margin compared to 2023, with operating expenses growing by 8%-10%. Cash used for operating activities is anticipated to be higher than in 2023. For Q3, software revenue is estimated to be $32M-$34M.
The mixed projections for FY 2024, including moderate revenue growth and increased operating expenses, suggest a neutral short-term impact on SDGR's stock price. The slight decrease in software gross margin and higher cash usage for operations could offset the positive revenue growth, leading to a balanced outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100